Medical Imaging

Physicians utilize medical imaging to see inside the body to diagnose and treat patients. This includes computed tomography (CT), magnetic resonance imaging (MRI), X-ray, ultrasound, fluoroscopy, angiography,  and the nuclear imaging modalities of PET and SPECT. 

Computer-aided assessment of DCE MR images predicts breast cancer survival

Volume and perfusion changes of breast cancers before and after neoadjuvant chemotherapy assessed with computer-aided evaluation of dynamic contrast agent-enhanced (DCE) MR images offer practical imaging parameters associated with survival, according to a study published in the September issue of Radiology.

ESPN pulls out of concussion documentary series

Sports news giant ESPN has ended its participation in a joint reporting project with PBS’ Frontline that was focused on concussions in the National Football League.

Short-interval follow-up not needed for MB circumscribed masses on screening US

Multiple bilateral (MB) circumscribed masses seen at screening ultrasound (US) are generally benign, with no malignancies observed in a recent study of more than 2,000 patients with an elevated risk for breast cancer, according to results published in the September issue of Radiology.

Siemens Healthcare introduces continuous FlowMotion PET-CT

Siemens Healthcare has launched its new Biograph mCT Flow – a groundbreaking PET-CT system. For the first time ever the system overcomes the limitations of conventional bed-based PET-CT with FlowMotion, an innovative new technology that moves the patient smoothly through the system’s gantry, while continuously acquiring PET data.

Navidea awarded NIH SBIR grant for NAV4694 beta-amyloid imaging agent phase III clinical program aimed at Alzheimer’s disease

Navidea Biopharmaceuticals announces award of a Small Business Innovation Research (SBIR) grant from the National Institute On Aging (NIA) of the National Institutes of Health (NIH) in connection with the Company's Phase 3 clinical program for its NAV4694 beta-amyloid imaging agent as an aid in the differential diagnosis of Alzheimer’s disease.

Navidea Biopharmaceuticals signs manufacturing agreement with Siemens’ PETNET Solutions for NAV4694 beta-amyloid imaging agent

Navidea has signed an agreement with Siemens’ PETNET Solutions that grants PETNET Solutions the right to manufacture Navidea’s Fluorine-18 labeled NAV4694, an investigational beta-amyloid PET imaging agent, which is currently being evaluated in Phase 2 and 3 clinical trials evaluating subjects with signs or symptoms of cognitive impairment such as Mild Cognitive Impairment and Alzheimer’s disease.

Regadenoson stress PET/CT MPI trumps SPECT for CAD detection

Regadenoson stress Rb-82 PET/CT myocardial perfusion imaging (MPI) is highly sensitive, 92 percent, for the detection of obstructive CAD and beats SPECT MPI, according to a study published online Aug. 12 in the Journal of Nuclear Medicine.

Atomic imaging reveals how flame retardants compete with estrogens in the body

Flame retardants mimic estradiols in the body, potentially causing havoc on natural endocrine homeostasis, according to new 3D x-ray crystallography research published online Aug. 19 in Environmental Health Perspectives.

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.